| Trial ID: | L7384 |
| Source ID: | NCT00411554
|
| Associated Drug: |
Sitagliptin Phosphate
|
| Title: |
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00411554/results
|
| Conditions: |
Diabetes Mellitus, Non-Insulin-Dependent
|
| Interventions: |
DRUG: sitagliptin phosphate|DRUG: Comparator: voglibose
|
| Outcome Measures: |
Primary: Change From Baseline in HbA1c at Week 12, HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent., Baseline and Week 12 | Secondary: Change From Baseline in Fasting Plasma Glucose at Week 12, Change from baseline at Week 12 is defined as fasting plasma glucose at Week 12 minus fasting plasma glucose at Week 0., Baseline and Week 12|Change From Baseline in 2 Hour Postprandial Glucose at Week 12, Change from baseline at Week 12 is defined as 2-hour postprandial glucose Week 12 minus 2-hour postprandial glucose Week 0., Baseline and Week 12
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
319
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-01
|
| Completion Date: |
2007-08
|
| Results First Posted: |
2009-09-25
|
| Last Update Posted: |
2016-02-05
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00411554
|
